Diamyd Medical granted European patent

The US Patent and Trademark Office (USPTO) has granted Prolight a patent for the analytical unit and reaction chamber for the company’s point-of-care analysis system, MicroFlex, which is being developed by Prolight’s partner TTP (The Technology Partnership).

The European Patent Office, EPO, has issued a decision to grant European patent for exidavnemab, a drug candidate being developed as a treatment for synucleinopathies such as Parkinson’s disease and Multiple System Atrophy (MSA).

The Unites States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent application with claims covering a method of treating rheumatoid arthritis (RA) with resomelagon (AP1189) in combination with methotrexate (MTX).

The company has been granted a patent by the European Patent Office (EPO) for GmPcides, a new class of synthetic antibacterials.

The United States Patent and Trademark Office (USPTO) has issued US patent 12,239,631 with claims covering the crystal form of resomelagon (AP1189) currently undergoing development in clinical phase 2b.

The company has been granted a patent in Australia for its medical technology innovation, marking a significant milestone in its international expansion it states.

Dignitana has received a Notice of Allowance from the Korean Intellectual Property Office for a patent titled “Scalp Cooling Apparatus, Method and System.”